-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immuno checkpoint inhibitors (ICI) are one of the most important milestones in cancer treatment.
for non-small cell lung cancer (NSCLC), ICI single-drug or combination with chemotherapy or other ICI can improve patient survival compared to chemotherapy alone, and is now the standard treatment for NSCLC.
the morphological evaluation of tumor-immersive lymphocytes (TIL) and the prognostic prognosticity of ICI or chemotherapy in patients with advanced NSCLC were not clear.
study is a multi-center retrospective study designed to analyze the correlation between TIL and the prognosticity of ICI or chemotherapy in patients with advanced NSCLC.
the study included two queues: 221 patients treated with navuda resistance between November 2012 and February 2017;
patients with tissues that can be used for intersted TIL evaluation.
high TIL count (high TIL) is defined as ≥ 10% density.
end point is total lifetime (OS).
64% were male, the middle age was 63, 82.3% were smokers, 77% had a performance status of ≤1 points, and 63% were adenocarcinoma.
high TIL rate of 22%, associated with OS and progress-free survival rate (PFS) (risk ratio of 0.48, 95% CI 0.28-0.81; 0.40, 95%CI 0.25-0.64)。
PFS in the high TIL group and the low TIL group were 13.0 months (95% CI 5.0-not reached) and 2.2 months (1.7-3.0), respectively, while the medium OS was not reached (12.2-not reached) and 8.4 months (5.0-11.6), respectively.
high TIL is associated with total efficiency (ORR) and disease control rate (DCR) (P.lt;0.0001).
in the chemotherapy queue, 69 percent were male, 89 percent were smokers, 86 percent were in ≤1 and 90 percent were adenocarcinoma.
high TIL is 37%.
PFS and OS were 5.7 months (95% CI 4.9-6.7) and 11.7 months (9.3-13.0), respectively, independent of TIL.
summary, in the real immunotherapy queue of NSCLC patients, high TIL was associated with a good prognosis, but independent of the prognosis of patients with chemotherapy, suggesting that TIL could be used to screen patients suitable for immunotherapy.
